All In Biotech

Drug Trial Radar · NCT07354022

A Study to Evluate Efficacy and Safety of HRS-8080 Combined With Dalpiciclib in Patients With Advanced or Metastatic Breast Cancer Resistant to Adjuvant Endocrine Therapy.

A Multicenter, Open-label, Randomized Controlled Phase III Clinical Study Evaluating the Efficacy and Safety of HRS-8080 Combined With Dalpiciclib Versus Fulvestrant Combined With Dalpiciclib in Patients With Locally Advanced or Metastatic Breast Cancer Resistant to Adjuvant Endocrine Therapy.

Last checked: Nov 19, 2026Latest source record: Jun 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 912 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

912

Planned (sponsor's estimate)

Start

May 5, 2026

Primary completion

Dec 2028

Study completion Dec 2031

Sponsor

Sponsor type
Industry
First posted
Jan 21, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is being conducted to evaluate the efficacy and safety of HRS-8080 combined with dalpiciclib versus fulvestrant combined with dalpiciclib in patients with locally advanced/metastatic breast cancer who had developed drug resistance to prior adjuvant endocrine therapy.

Conditions

  • Locally Advanced or Metastatic Breast Cancer

Interventions

  • HRS-8080 Tablet ; Dalpiciclib IsethionateDrug

    * HRS-8080 Tablet * Dalpiciclib Isethionate

  • Fulvestrant injection ;Dalpiciclib IsethionateDrug

    * Fulvestrant injection * Dalpiciclib Isethionate

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Investigator assessed Progression free survival (PFS)Time frame: Up to 5 years.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Chinese PLA General Hospital Fifth Medical Center

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.